Open AccessRisk of Febuxostat-Associated Myopathy in Patients with CKD
Author(s) -
Chung-Te Liu,
ChunYou Chen,
ChienYi Hsu,
PoHsun Huang,
FengYen Lin,
JawWen Chen,
ShingJong Lin
Publication year - 2017
Publication title -
clinical journal of the american society of nephrology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.755
H-Index - 151
eISSN - 1555-905X
pISSN - 1555-9041
DOI - 10.2215/cjn.08280816
Subject(s) - febuxostat , medicine , myopathy , kidney disease , hyperuricemia , odds ratio , rhabdomyolysis , retrospective cohort study , uric acid
Febuxostat, a nonpurine xanthine oxidase inhibitor, is widely used to treat hyperuricemia. Although febuxostat-associated rhabdomyolysis was reported in some patients with CKD, the association between CKD and febuxostat-associated myopathy remains uncertain.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom